---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-302150"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2023-12-22T23:59:59+00:00"
generated_at: "2026-06-07T08:36:00.001180+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Mylan files ANDA for generic APONVIE; Heron to defend 10 patents

## Summary
- Mylan filed paragraph IV certification notice for generic version of APONVIE (aprepitant).
- Heron will file patent infringement lawsuit within 45 days of December 18, 2023 notice.
- 10 Orange Book-listed patents expiring September 18, 2035 are challenged as invalid or not infringed.
- FDA approval of Mylan's ANDA stayed for 7.5 years if suit is timely filed, absent court ruling.

## SEC filing metadata
- accession: 0001193125-23-302150
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2023-12-22T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000119312523302150/0001193125-23-302150-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000119312523302150/d668785d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-302150
- JSON: https://secwatch.observer/filing/0001193125-23-302150.json
- Plain text: https://secwatch.observer/filing/0001193125-23-302150.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.